{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T06:28:48Z","timestamp":1783232928668,"version":"3.54.6"},"reference-count":36,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T00:00:00Z","timestamp":1718150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>X-linked hypophosphatemia (XLH) is a rare genetic bone disease affecting both children and adults, with oral manifestations such as spontaneous dental infections. The main treatments for XLH are conventional treatment (CT) with oral phosphate salts and active vitamin D supplementation and burosumab, an antibody targeting fibroblast growth factor 23. While the beneficial effect of CT on oral manifestations is established, the effect of burosumab on oral health is unknown, especially in adults.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We aimed to compare the oral health (number of missing or endodontically treated teeth and presence of periodontal disease) and incidence of endodontic infections of adult patients with XLH according to their treatment's modalities (no treatment, CT, or burosumab).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was achieved through a single-center, retrospective analysis of oral health data from 44 patients who had undergone dental monitoring for at least 6 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Oral health varied according to the proportion of their adult life spent under treatment for XLH, and the incidence of dental infections during follow-up was influenced by the type of treatment received. There was a 55.9% reduction of infections during CT and an 86.4% reduction during burosumab treatment compared to periods with no treatment (P &amp;lt; .0001). Comparing treatment and nontreatment periods within the same patient showed a strong association between burosumab treatment and decreased infection incidence (.006 vs .09 infection per month, P &amp;lt; .01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We observed that adults with XLH treated with burosumab developed fewer endodontic infections during dental follow-up than patients who were untreated or received CT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae398","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T11:31:55Z","timestamp":1718191915000},"page":"1460-1467","source":"Crossref","is-referenced-by-count":15,"title":["Improved Oral Health in Adults With X-Linked Hypophosphatemia Treated With Burosumab"],"prefix":"10.1210","volume":"110","author":[{"given":"Agathe","family":"Herv\u00e9","sequence":"first","affiliation":[{"name":"UFR Odontologie, Universit\u00e9 Paris Cit\u00e9 and AP-HP, Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network, FHU DDS-net, ERN BOND, Department of Dental Medicine, Bretonneau Hospital , 75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Gadion","sequence":"additional","affiliation":[{"name":"UFR Odontologie, Universit\u00e9 Paris Cit\u00e9 and AP-HP, Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network, FHU DDS-net, ERN BOND, Department of Dental Medicine, Bretonneau Hospital , 75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-9503","authenticated-orcid":false,"given":"Julia","family":"Herrou","sequence":"additional","affiliation":[{"name":"UFR de m\u00e9decine, Universit\u00e9 Paris Cit\u00e9 and AP-HP, Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network, ERN BOND, Department of Rheumatology, Cochin Hospital , 75014 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Izart","sequence":"additional","affiliation":[{"name":"UFR Odontologie, Universit\u00e9 Paris Cit\u00e9 and AP-HP, Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network, FHU DDS-net, ERN BOND, Department of Dental Medicine, Bretonneau Hospital , 75018 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3455-002X","authenticated-orcid":false,"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[{"name":"AP-HP, Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network, Endo-ERN and ERN BOND, Department of Endocrinology and Diabetology for Children, Bic\u00eatre Paris Saclay Hospital and Universit\u00e9 Paris Saclay, INSERM UMR 1185 , 94270 Le Kremlin Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Cohen-Solal","sequence":"additional","affiliation":[{"name":"AP-HP, Reference Center for Rare Bone Diseases, OSCAR Network, Department of Rheumatology, Lariboisiere Hospital and Universit\u00e9 Paris Cit\u00e9, INSERM 1132 , 75010 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8630-961X","authenticated-orcid":false,"given":"Anne-Lise","family":"Lecoq","sequence":"additional","affiliation":[{"name":"AP-HP, Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network, Endo-ERN and ERN BOND, Department of Endocrinology, Bic\u00eatre Paris Saclay Hospital and Universit\u00e9 Paris Saclay, INSERM UMR 1185 , 94270 Le Kremlin Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4226","authenticated-orcid":false,"given":"Peter","family":"Kamenicky","sequence":"additional","affiliation":[{"name":"AP-HP, Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network, Endo-ERN and ERN BOND, Department of Endocrinology, Bic\u00eatre Paris Saclay Hospital and Universit\u00e9 Paris Saclay, INSERM UMR 1185 , 94270 Le Kremlin Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6238-2601","authenticated-orcid":false,"given":"Karine","family":"Briot","sequence":"additional","affiliation":[{"name":"UFR de m\u00e9decine, Universit\u00e9 Paris Cit\u00e9 and AP-HP, Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network, ERN BOND, Department of Rheumatology, Cochin Hospital , 75014 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3463-3936","authenticated-orcid":false,"given":"Catherine","family":"Chaussain","sequence":"additional","affiliation":[{"name":"UFR Odontologie, Universit\u00e9 Paris Cit\u00e9 and AP-HP, Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network, FHU DDS-net, ERN BOND, Department of Dental Medicine, Bretonneau Hospital , 75018 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Cit\u00e9, Laboratory URP2496 Orofacial Pathologies, Imaging and Biotherapies , 92120 Montrouge ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-3970","authenticated-orcid":false,"given":"Martin","family":"Biosse Duplan","sequence":"additional","affiliation":[{"name":"UFR Odontologie, Universit\u00e9 Paris Cit\u00e9 and AP-HP, Reference Center for Rare Diseases of the Calcium and Phosphate Metabolism, OSCAR Network, FHU DDS-net, ERN BOND, Department of Dental Medicine, Bretonneau Hospital , 75018 Paris ,","place":["France"]},{"name":"Institut Imagine, INSERM 1163 , 75015 Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"issue":"1","key":"2025042208271501000_dgae398-B1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13023-019-1014-8","article-title":"FGF23 and its role in X-linked hypophosphatemia-related morbidity","volume":"14","author":"Beck-Nielsen","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2025042208271501000_dgae398-B2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.57582\/IJBF.210102.074","article-title":"Dental and periodontal features and management in XLH children and adults","volume":"1","author":"Biosse Duplan","year":"2021","journal-title":"Int J Bone Fragility"},{"issue":"1","key":"2025042208271501000_dgae398-B3","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect"},{"issue":"5","key":"2025042208271501000_dgae398-B4","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1601-0825.2006.01326.x","article-title":"Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment","volume":"13","author":"Chaussain-Miller","year":"2007","journal-title":"Oral Dis"},{"issue":"2","key":"2025042208271501000_dgae398-B5","first-page":"61","article-title":"Prevalence and pathogenesis of dental and periodontal lesions in children with X-linked hypophosphatemic rickets","volume":"7","author":"Baroncelli","year":"2006","journal-title":"Eur J Paediatr Dent"},{"issue":"1","key":"2025042208271501000_dgae398-B6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1365-263X.1998.00059.x","article-title":"Dental problems associated with hypophosphataemic vitamin D resistant rickets","volume":"8","author":"Goodman","year":"1998","journal-title":"Int J Paediatr Dent"},{"issue":"7","key":"2025042208271501000_dgae398-B7","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","article-title":"Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia","volume":"15","author":"Haffner","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"10189","key":"2025042208271501000_dgae398-B8","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","article-title":"Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"issue":"21","key":"2025042208271501000_dgae398-B9","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","article-title":"Burosumab therapy in children with X-linked hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2025042208271501000_dgae398-B10","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1210\/clinem\/dgab729","article-title":"Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia","volume":"107","author":"Linglart","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025042208271501000_dgae398-B11","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis: EFFICACY OF BUROSUMAB IN ADULTS WITH XLH","volume":"33 (8)","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2025042208271501000_dgae398-B12","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/jbmr.3843","article-title":"Burosumab improved histomorphometric measures of osteomalacia in adults with X-linked hypophosphatemia: a phase 3, single-arm","volume":"34","author":"Insogna","year":"2019","journal-title":"Int Trial J Bone Miner Res"},{"key":"2025042208271501000_dgae398-B13","doi-asserted-by":"crossref","first-page":"e001714","DOI":"10.1136\/rmdopen-2021-001714","article-title":"Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension","volume":"7 (3)","author":"Briot","year":"2021","journal-title":"RMD Open"},{"issue":"1","key":"2025042208271501000_dgae398-B14","doi-asserted-by":"crossref","first-page":"e002676","DOI":"10.1136\/rmdopen-2022-002676","article-title":"Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment","volume":"9","author":"Kamenicky","year":"2023","journal-title":"RMD Open"},{"issue":"4","key":"2025042208271501000_dgae398-B15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00223-022-01006-7","article-title":"Efficacy of burosumab in adults with X-linked hypophosphatemia (XLH): a post hoc subgroup analysis of a randomized double-blind placebo-controlled phase 3 study","volume":"111","author":"Brandi","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2025042208271501000_dgae398-B16","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1067\/mpd.2003.119","article-title":"Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D","volume":"142","author":"Chaussain-Miller","year":"2003","journal-title":"J Pediatr"},{"issue":"8","key":"2025042208271501000_dgae398-B17","doi-asserted-by":"crossref","first-page":"e3241","DOI":"10.1210\/clinem\/dgac296","article-title":"Impact of burosumab compared with conventional therapy in younger versus older children with X-linked hypophosphatemia","volume":"107","author":"Ward","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025042208271501000_dgae398-B18","doi-asserted-by":"crossref","first-page":"e10672","DOI":"10.1002\/jbm4.10672","article-title":"Burosumab and dental abscesses in children with X-linked hypophosphatemia","volume":"6","author":"Gadion","year":"2022","journal-title":"JBMR Plus"},{"issue":"10","key":"2025042208271501000_dgae398-B19","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1210\/JC.2015-2199","article-title":"Conventional therapy in adults with X-linked hypophosphatemia: effects on enthesopathy and dental disease","volume":"100","author":"Connor","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025042208271501000_dgae398-B20","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/0022034516677528","article-title":"Phosphate and vitamin D prevent periodontitis in X-linked hypophosphatemia","volume":"96","author":"Biosse Duplan","year":"2017","journal-title":"J Dent Res"},{"key":"2025042208271501000_dgae398-B21","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1111\/jcpe.12946","article-title":"Periodontitis: consensus report of workgroup 2 of the 2017 world workshop on the classification of periodontal and peri-implant diseases and conditions","volume":"45","author":"Papapanou","year":"2018","journal-title":"J Clin Periodontol"},{"key":"2025042208271501000_dgae398-B22","unstructured":"Biosse Duplan M . Manuscript Herve_supplementary_material.doc. 2024. Accessed June 14, 2024. 10.6084\/m9.figshare.26048779.v1. 2024."},{"issue":"1","key":"2025042208271501000_dgae398-B23","doi-asserted-by":"crossref","first-page":"e210564","DOI":"10.1530\/EC-21-0564","article-title":"Oral health-related quality of life in patients with X-linked hypophosphatemia: a qualitative exploration","volume":"11","author":"Nguyen","year":"2022","journal-title":"Endocr Connect"},{"issue":"2","key":"2025042208271501000_dgae398-B24","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/joor.13114","article-title":"Oral health-related quality of life in X-linked hypophosphataemia and osteogenesis Imperfecta","volume":"48","author":"Gj\u00f8rup","year":"2021","journal-title":"J Oral Rehabil"},{"issue":"3","key":"2025042208271501000_dgae398-B25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2025042208271501000_dgae398-B26","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1210\/js.2018-00365","article-title":"The lifelong impact of X-linked hypophosphatemia: results from a burden of disease survey","volume":"3","author":"Skrinar","year":"2019","journal-title":"J Endocr Soc"},{"key":"2025042208271501000_dgae398-B27","author":"Jeanblanc"},{"issue":"6","key":"2025042208271501000_dgae398-B28","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1210\/clinem\/dgac732","article-title":"Effect of conventional treatment on dental complications and ectopic ossifications among 30 adults with XLH","volume":"108","author":"Kato","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025042208271501000_dgae398-B29","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1210\/clinem\/dgab580","article-title":"Prevalence of enthesopathies in adults with X-linked hypophosphatemia: analysis of risk factors","volume":"107","author":"Herrou","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2025042208271501000_dgae398-B30","doi-asserted-by":"crossref","first-page":"1211426","DOI":"10.3389\/fendo.2023.1211426","article-title":"Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives","volume":"14","author":"Seefried","year":"2023","journal-title":"Front Endocrinol"},{"issue":"1","key":"2025042208271501000_dgae398-B31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1601-1546.2012.00269.x","article-title":"Dentin basic structure and composition\u2014an overview","volume":"20","author":"Tj\u00e4derhane","year":"2009","journal-title":"Endod Top"},{"issue":"1","key":"2025042208271501000_dgae398-B32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41368-023-00259-8","article-title":"Dental impact of anti-fibroblast growth factor 23 therapy in X-linked hypophosphatemia","volume":"15","author":"Lira Dos Santos","year":"2023","journal-title":"Int J Oral Sci"},{"key":"2025042208271501000_dgae398-B33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.bone.2017.07.026","article-title":"Tissue-specific mineralization defects in the periodontium of the hyp mouse model of X-linked hypophosphatemia","volume":"103","author":"Coyac","year":"2017","journal-title":"Bone"},{"issue":"3","key":"2025042208271501000_dgae398-B34","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1172\/JCI83470","article-title":"FGF23 signaling impairs neutrophil recruitment and host defense during CKD","volume":"126","author":"Rossaint","year":"2016","journal-title":"J Clin Invest"},{"key":"2025042208271501000_dgae398-B35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3389\/fendo.2018.00189","article-title":"FGF23 actions on target tissues\u2014with and without klotho","volume":"9","author":"Richter","year":"2018","journal-title":"Front Endocrinol"},{"issue":"11","key":"2025042208271501000_dgae398-B36","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1902\/jop.2011.100736","article-title":"Periodontal status of patients with hypophosphatemic rickets: a case series","volume":"82","author":"Ye","year":"2011","journal-title":"J Periodontol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae398\/58319409\/dgae398.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/5\/1460\/58319409\/dgae398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/5\/1460\/58319409\/dgae398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T12:27:42Z","timestamp":1745324862000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/5\/1460\/7691585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,6,12]]},"published-print":{"date-parts":[[2025,4,22]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae398","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,6,12]]}}}